Search

Your search keyword '"Meiler J"' showing total 618 results
Start Over Author "Meiler J"
618 results on '"Meiler J"'

2. Millifluidic magnetophoresis-based chip for agespecific fractionation: evaluating the impact of age on metabolomics and gene expression in yeast.

Author

Wittmann, L., Eigenfeld, M., Büchner, K., Meiler, J., Habisch, H., Madl, T., Kerpes, R., Becker, T., Berensmeier, S., and Schwaminger, S. P.

Subjects
GENE expression, YEAST culture, YEAST, CELLULAR aging, CELL fractionation, METABOLOMICS, PROTEIN fractionation
Abstract

A novel millifluidic process introduces age-based fractionation of S. pastorianus var. carlsbergensis yeast culture through magnetophoresis. Saccharomyces yeast is a model organism for aging research used in various industries. Traditional age-based cell separation methods were labor-intensive, but techniques like magnetic labeling have eased the process by being non-invasive and scalable. Our approach introduces an age-specific fractionation using a 3D-printed millfluidic chip in a two-step process, ensuring efficient cell deflection in the magnetic field and counteracting magnetic induced convection. Among various channel designs, the pinchshaped channel proved most effective for age differentiation based on magnetically labeled bud scar numbers. Metabolomic analyses revealed changes in certain amino acids and increased NAD+ levels, suggesting metabolic shifts in aging cells. Gene expression studies further underlined these age-related metabolic changes. This innovative platform offers a high-throughput, non-invasive method for age-specific yeast cell fractionation, with potential applications in industries ranging from food and beverages to pharmaceuticals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Author

Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., and Lorenzen, S.

Published
2020
Full Text
View/download PDF

5. Outcome of the First wwPDB Hybrid/Integrative Methods Task Force Workshop

Author

Sali, A, Berman, HM, Schwede, T, Trewhella, J, Kleywegt, G, Burley, SK, Markley, J, Nakamura, H, Adams, P, Bonvin, AMJJ, Chiu, W, Peraro, MD, Di Maio, F, Ferrin, TE, Grünewald, K, Gutmanas, A, Henderson, R, Hummer, G, Iwasaki, K, Johnson, G, Lawson, CL, Meiler, J, Marti-Renom, MA, Montelione, GT, Nilges, M, Nussinov, R, Patwardhan, A, Rappsilber, J, Read, RJ, Saibil, H, Schröder, GF, Schwieters, CD, Seidel, CAM, Svergun, D, Topf, M, Ulrich, EL, Velankar, S, and Westbrook, JD

Subjects
Biophysics, Biological Sciences, Information and Computing Sciences, Chemical Sciences
Abstract

Structures of biomolecular systems are increasingly computed by integrative modeling that relies on varied types of experimental data and theoretical information. We describe here the proceedings and conclusions from the first wwPDB Hybrid/Integrative Methods Task Force Workshop held at the European Bioinformatics Institute in Hinxton, UK, on October 6 and 7, 2014. At the workshop, experts in various experimental fields of structural biology, experts in integrative modeling and visualization, and experts in data archiving addressed a series of questions central to the future of structural biology. How should integrative models be represented? How should the data and integrative models be validated? What data should be archived? How should the data and models be archived? What information should accompany the publication of integrative models?

Published
2015

7. Maligne Hodentumoren

Author

Albers, P., Beyer, J., Claßen, J., Dieckmann, K.-P., Gauler, T., Hartmann, J.T., Hartmann, M., Heidenreich, A., Krege, S., Kuczyk, M.A., Mayer, F., Meiler, J., Merseburger, A.S., Schuler, M., Seeber, S., Souchon, R., Stöckle, M., and Rübben, Herbert, editor

Published
2014
Full Text
View/download PDF

11. LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

Author

Kasper-Virchow, S., Hofheinz, R.D., Stintzing, S., Dechow, T.N., Ettrich, T.J., Sinn, M., Roderburg, C., Fischer von Weikersthal, L., Graeven, U., Mueller, C., Meiler, J., Stein, A., Modest, D.P., Pauligk, C., Virchow, I., Siveke, J.T., Al-Batran, S-E., Schuler, M.H.H., and Goetze, T.O.

Published
2024
Full Text
View/download PDF

13. Integrative model of the FSH receptor reveals the structural role of the flexible hinge region

Author

Nagel, Marcus, Moretti, R., Paschke, R., von Bergen, Martin, Meiler, J., Kalkhof, Stefan, Nagel, Marcus, Moretti, R., Paschke, R., von Bergen, Martin, Meiler, J., and Kalkhof, Stefan

Abstract

The follicle-stimulating hormone receptor (FSHR) belongs to the glycoprotein hormone receptors, a subfamily of G-protein-coupled receptors (GPCRs). FSHR is involved in reproductive processes such as gonadal development and maturation. Structurally, the extensive extracellular domain, which contains the hormone-binding site and is linked to the transmembrane domain by the hinge region (HR), is characteristic for these receptors. How this HR is involved in hormone binding and signal transduction is still an open question. We combined in vitro and in situ chemical crosslinking, disulfide pattern analysis, and mutation data with molecular modeling to generate experimentally driven full-length models. These models provide insights into the interface, important side-chain interactions, and activation mechanism. The interface indicates a strong involvement of the connecting loop. A major rearrangement of the HR seems implausible due to the tight arrangement and fixation by disulfide bonds. The models are expected to allow for testable hypotheses about signal transduction and drug development for GPHRs.

Published
2022

14. The Collagen Receptor Discoidin Domain Receptor 1b Enhances Integrin β1-Mediated Cell Migration by Interacting With Talin and Promoting Rac1 Activation

Author

Borza, CM, Bolas, G, Zhang, X, Browning Monroe, MB, Zhang, M-Z, Meiler, J, Skwark, MJ, Harris, RC, Lapierre, LA, Goldenring, JR, Hook, M, Rivera, J, Brown, KL, Leitinger, B, Tyska, MJ, Moser, M, Böttcher, RT, Zent, R, Pozzi, A, and Biotechnology and Biological Sciences Research Council (BBSRC)

Subjects
receptor activation, extracellular matrix, ddc:570, integrins, receptor tyrosine kinase, Cell Biology, migration, receptor tyrosine kinase, integrins, extracellular matrix, migration, receptor activation, Rac1, Rac1, Developmental Biology
Abstract

Integrins and discoidin domain receptors (DDRs) 1 and 2 promote cell adhesion and migration on both fibrillar and non fibrillar collagens. Collagen I contains DDR and integrin selective binding motifs; however, the relative contribution of these two receptors in regulating cell migration is unclear. DDR1 has five isoforms (DDR1a-e), with most cells expressing the DDR1a and DDR1b isoforms. We show that human embryonic kidney 293 cells expressing DDR1b migrate more than DDR1a expressing cells on DDR selective substrata as well as on collagen I in vitro. In addition, DDR1b expressing cells show increased lung colonization after tail vein injection in nude mice. DDR1a and DDR1b differ from each other by an extra 37 amino acids in the DDR1b cytoplasmic domain. Interestingly, these 37 amino acids contain an NPxY motif which is a central control module within the cytoplasmic domain of β integrins and acts by binding scaffold proteins, including talin. Using purified recombinant DDR1 cytoplasmic tail proteins, we show that DDR1b directly binds talin with higher affinity than DDR1a. In cells, DDR1b, but not DDR1a, colocalizes with talin and integrin β1 to focal adhesions and enhances integrin β1-mediated cell migration. Moreover, we show that DDR1b promotes cell migration by enhancing Rac1 activation. Mechanistically DDR1b interacts with the GTPase-activating protein (GAP) Breakpoint cluster region protein (BCR) thus reducing its GAP activity and enhancing Rac activation. Our study identifies DDR1b as a major driver of cell migration and talin and BCR as key players in the interplay between integrins and DDR1b in regulating cell migration.

Published
2022

17. 679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)

Author

Darr, C., primary, Zschäbitz, S., additional, Ivanyi, P., additional, Wirth, M., additional, Staib, P., additional, Schostak, M., additional, Müller, L., additional, Metz, M., additional, Bergmann, L., additional, Steiner, T., additional, Lorch, A., additional, Schütt, P., additional, Rafiyan, M-R., additional, Hellmis, E., additional, Hinke, A., additional, Mänz, M., additional, Meiler, J., additional, Kretz, T., additional, Flörcken, A., additional, and Grünwald, V., additional

Published
2021
Full Text
View/download PDF

18. NIVOSWITCH : Phase II trial investigating nivolumab maintenance after TKI induction in metastatic renal cell carcinoma (mRCC) ; final results on efficacy and patient reported outcomes (PRO)

Author

Ivanyi, P., Darr, Christopher, Gruellich, C., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Mueller, L., Metz, M., Bergmann, L., Steiner, T., Welslau, M., Lorch, A., Schütt, Philipp, Mohammad-Reza, R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Loidl, W., Floercken, A., and Grünwald, Viktor

Subjects
Medizin
Published
2021

19. Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)

Author

Darr, C., Zschäbitz, S., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Müller, L., Metz, M., Bergmann, L., Steiner, T., Lorch, A., Schütt, P., Rafiyan, M-R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Flörcken, A., and Grünwald, V.

Subjects
Medizin
Published
2021

21. 1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)

Author

Darr, C., Ivanyi, P., Wirth, M., Zschäbitz, S., Schostak, M., Mueller, L., Steiner, T., Welslau, M.K., Schuett, P., Lorch, A., Rafiyan, M-R., Hellmis, E., Meiler, J., Kretz, T., Loidl, W.C., Floercken, A., Stöhr, C.G., Eckstein, M., Hartmann, A., and Grünwald, V.

Published
2023
Full Text
View/download PDF

23. WTZ-Tumorprofil - A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center: Two yearsʼ experience.: ID 085

Author

Wiesweg, M., Ting, S., Reis, H., Worm, K., Kasper, S., Bauer, S., Gauler, T. C., Welt, A., Richly, H., Tewes, M., Meiler, J., Hense, J., Eberhardt, W. E., Derks, C., Cortes-Incio, D., Skottky, S., Wohlschläger, J., Breitenbücher, F., Freitag, L., Stamatis, G., Schmid, K. W., and Schuler, M.

Published
2014

27. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

38. Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study

Author

Pape, U.-F., primary, Kasper, S., additional, Meiler, J., additional, Sinn, M., additional, Vogel, A., additional, Mueller, L., additional, Burkhard, O., additional, Caca, K., additional, Heeg, S., additional, Rodriguez Laval, V., additional, Kuhl, A.A., additional, Arsenic, R., additional, Jansen, H., additional, Mehrling, T., additional, Hilgier, K., additional, Wagner, I., additional, and Utku, N., additional

Published
2019
Full Text
View/download PDF

39. A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)

Author

Grünwald, V., primary, Grüllich, C., additional, Ivanyi, P., additional, Wirth, M., additional, Staib, P., additional, Schostak, M., additional, Dargatz, P., additional, Müller, L., additional, Metz, M., additional, Bergmann, L., additional, Welslau, M.K., additional, Schütt, P., additional, Rafiyan, M.-R., additional, Hellmis, E., additional, Hinke, A., additional, Meiler, J., additional, Kretz, T., additional, Loidl, W.C., additional, Flörcken, A., additional, and Steiner, T., additional

Published
2019
Full Text
View/download PDF

40. Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth

Author

Hanker, AB, primary, Koch, JP, additional, Ye, D, additional, Sliwoski, G, additional, Sheehan, J, additional, Kinch, LN, additional, Red Brewer, M, additional, He, J, additional, Miller, VA, additional, Lalani, AS, additional, Cutler, RE, additional, Croessmann, S, additional, Zabransky, DJ, additional, Meiler, J, additional, and Arteaga, CL, additional

Published
2019
Full Text
View/download PDF

41. Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Author

Welslau, M.K., primary, Zaiss, M., additional, Söling, U., additional, Untch, M., additional, Müller, L., additional, Lüftner, D., additional, Meiler, J., additional, Welt, A., additional, Sahlmann, J., additional, Houet, L., additional, Runkel, E., additional, and Marschner, N.W., additional

Published
2018
Full Text
View/download PDF

42. Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

Author

Moehler, M., primary, Maderer, A., additional, Thuss-Patience, P., additional, Brenner, B., additional, Hecker, J., additional, Muñoz, F. Longo, additional, Meiler, J., additional, Ettrich, T., additional, Hofheinz, R., additional, Al-Batran, S., additional, Vogel, A., additional, Mueller, L., additional, Lutz, M., additional, Borchert, K., additional, Greil, R., additional, Alsina, M., additional, Karatas, A., additional, Van Cutsem, E., additional, Keller, R., additional, Larcher-Senn, J., additional, and Lorenzen, S., additional

Published
2018
Full Text
View/download PDF

43. Therapeutic human monoclonal antibody MR191 bound to a marburgvirus glycoprotein

Author

King, L.B., primary, Fusco, M.L., additional, Flyak, A.I., additional, Ilinykh, P.A., additional, Huang, K., additional, Gunn, B., additional, Kirchdoerfer, R.N., additional, Hastie, K.M., additional, Sangha, A.K., additional, Meiler, J., additional, Alter, G., additional, Bukreyev, A., additional, Crowe, J.E.J., additional, and Saphire, E.O., additional

Published
2018
Full Text
View/download PDF

46. NMR solution structure of non-bound [des-Arg10]-kallidin (DAKD)

Author

Richter, C., primary, Jonker, H.R.A., additional, Schwalbe, H., additional, Joedicke, L., additional, Mao, J., additional, Kuenze, G., additional, Reinhart, C., additional, Kalavacherla, T., additional, Meiler, J., additional, Preu, J., additional, Michel, H., additional, and Glaubitz, C., additional

Published
2018
Full Text
View/download PDF

49. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Author

Eichhorst, Barbara F, Fischer, Kirsten, Fink, Anna Maria, Elter, Thomas, Wendtner, Clemens M, Goede, Valentin, Bergmann, Manuela, Stilgenbauer, Stephan, Hopfinger, Georg, Ritgen, Matthias, Bahlo, Jasmin, Busch, Raymonde, Hallek, Michael, Oduncu, F, Dreyling, M, Forstpointner, R, Schneller, F, Bogner, C, Peschel, C, Ringshausen, I, Götze, K, Goebeler, Me, Rückle, Lanz, Ritgen, M, Schawitzke, A, Heydrich, B, Kern, K, Böttcher, S, Irmer, S, Strack, U, Borries, V, Klima, Km, Scholz, C, Herold, M, Härtwig, K, Dürig, J, Dührsen, U, Müller Beissenhirtz, H, Noppeney, R, Schüttrumpf, S, Hohloch, K, Binder, C, Hasenkamp, J, Trümper, L, Bäsecke, J, Rieger, M, Witzens Harig, M, Friedrichs, B, Rieger, K, Uharek, L, Kubuschok, B, Murawski, N, Held, G, Zwick, C, Pfreundschuh, M, Fingerle Rowson, G, Reiser, M, Elter, T, Eichhorst, B, Pallasch, C, Hallek, M, Borchmann, P, Hacker, U, Schinkel, S, Wieker, K, Sökler, M, Wolf, Hh, Eucker, J, Staib, P, Schlegel, F, Kropff, M, Kahl, C, Hess, G, Beck, J, Wölfel, T, Bokemeyer, C, Schilling, G, Dierlamm, J, Schüler, F, Busemann, C, Dölken, G, Trendelenburg, Tk, Bühler, A, Stilgenbauer, S, Viardot, A, Greiner, J, Zenz, T, Gaidzik, V, Langer, C, Döhner, H, Werner, I, Dienst, A, Habersang, K, Härtel, N, Leitner, A, Kehrer, G, Middeke, H, Heinisch, K, Adorf, D, Ismer, B, Hering Schubert, C, Jäckle, J, Aulmann, C, Söllner, S, Majunke, P, Fuss, H, Käfer, G, Potenberg, J, Dietrich, G, Hartung, E, Pronath, A, Riedhammer, Fj, Zehrfeld, T, Prümmer, O, Gatter, J, Meier, A, Wattad, M, Heit, W, Sauer, I, Hilgers, K, Geissler, M, Bauer, J, Stein, W, Voigtmann, R, Natt, F, Nickelsen, M, Zeis, M, Schmitz, N, Lange, E, Stoltefuss, A, Schubert, J, Dürk, Ha, Kloke, O, Fauser, A, Roemer, E, Kraut, L, Musch, E, Kohl, S, Link, H, Kirsch, Jf, Schatz, M, Mezger, J, Kempf, B, Heil, G, Derigs, Hg, Roll, C, Kettner, E, Dübbers, Hw, Lutz, L, Hentrich, M, Hoffmann, U, Ibe, M, Falge, C, Schäfer Eckart, K, Rothmann, F, Raghavachar, A, Beckmann, K, Behringer, D, Stauder, H, Hempfling, C, Matzdorff, A, Hähling, D, Kaesberger, Kj, Mück, R, Waladkhani, Ar, Clemens, M, Kraft, J, Ehlert, T, N. N., Schloen, A, Sandritter, B, Scholz, Diekmann, C, Pflüger, Kh, Hausner, G, Fetscher, S, Aulitzky, W, Brugger, W, Frickhofen, N, Fuhr, Lange, C, Lambertz, H, Schulz, L, Schmier, M, Bentz, M, Tauchmann, Gm, Schmidt, M, Meiler, J, Sandmann, M, Kürschner, D, Maier Bay, B, Lindemann, W, Diers, J, Riemeier Sievers, C, Daun, M, Mergenthaler, Hg, Hiller, S, Schirmer, V, Kirchner, H, Langer, W, Günther, B, Gassmann, W, Franke, K, Burghardt, F, Abele, U, Celikel Becker, D, von Weikersthal LF, Brög, G, Hauch, U, Heinrich, B, Brudler, O, Häcker, B, Eckart, Mj, Bolouri, H, Göttler, B, Kindler, M, Zuchold, K, Strohbach, F, Plingen, Ml, Seibt Jung, H, Kirsch, A, Herrenberger, J, Doering, G, von Grünhagen, U, Franke, H, Weniger, J, Kerzel, W, Schmalfeld, M, Rohrberg, R, Hurtz, Hj, Gehbauer, G, Hahnfeld, S, Vehling Kaiser, U, Abenhardt, W, Bosse, D, Böning, L, Schmidt, B, Schick, Hd, Jacobs, G, Stauch, M, Hoffmann, R, Müller, S, Hahn, M, Freier, W, Dietzfelbinger, H, Rassmann, I, Söling, U, Siehl, S, Rudolph, R, Weinert, R, Sauer, A, Meyer, B, Eschenburg, H, Schadeck Gressel, C, Grabenhorst, U, Perker, M, Otremba, B, Reschke, D, Hinrichs, Hf, Zirpel, I, Höring, E, Respondek, M, Köppler, H, Heymanns, J, Weide, R, Hünermund, K, Thiel, C, Reiber, T, Spohn, C, Springer, G, Fiechtner, H, Hübner, A, Kurschel, E, Weiss, J, Schlag, R, Schäfer, E, Hartwich, G, Schmitz, S, Steinmetz, T, Kim, Ts, Lerchenmüller, C, Wehmeyer, J, Laubenstein, Hp, Rendenbach, B, Lebahn, H, Kröning, H, Uhle, R, Balló, H, Gaede, B, Zumbrink, S, Eckert, R, Kamp, T, Reimann, B, Burkhard, O, Mittermüller, J, Hansen, R, Hitz, H, Schliesser, G, Schmitt, Hr, Forstbauer, H, Grundeis, M, Schulze, M, Baldus, M, Lakner, V, Haen, M, Müller, C, Dörfel, S, Göhler, T, Welslau, M, Achtzehn, V, Culmann, H, Gerhardt, S, Ulshöfer, T, Koschuth, A, Schmidt, P, Müller, L, Schneider, M, Koniczek, K, Porowski, P, Glados, M, Knoblich, J, Ben Yehuda, D, Jäger, U, Gaiger, A, Schwarzmeier, J, Nösslinger, T, Smith, M, Patton, N, Gibbons, S, Bouabdallah, R, Gandhi, M, Marlton, P, Mills, T, Angelucci, E, Sorano, Gg, Casula, P, Berneman, Z, Kohser, P, Hudcova Burgetova, A, Machová, R, Papajik, T, Kubová, Z, Fineman, R, Mayer, J, Doubek, M, Brychtova, Y, Ciceri, F, Caligaris Cappio, F, Crocchiolo, R, Dauriac, C, Bernard, M, Escoffre Barbe, M, Lamy, T, Zikesova, E, Karban, J, Salkova, J, Trnený, M, Pytlik, R, Tiley, C, Forsyth, C, Vokurka, S, Koza, V, Van Hoof, A, Selleslag, D, Sebban, C, Baker, B, Belada, D, Jebavy, L, Smolej, L, Pavel, Z, Di Ianni, M, Castaigne, S, Del Poeta, G, Amadori, S, Catalano, J, Ganju, V, Hertzberg, M, Laurenti, L, Dalseg, Am, Bron, D, Morton, J, Durrant, S, Casado, Lf, Theunissen, K, Atias, D, Berkhan, L, Seymour, J, Wolf, M, Bosly, A, Osma Cordoba MM, Portois, C, Jaubert, J, Ferrant, A, Lambert, C, Maerevoet, E, Van den Neste, E, Gadeberg, O, Carney, B, Cannell, P, Eghbali, H, Legouffe, E, Bordessoule, D, Chaury, M, Moreau, S, Pierri, I, Gobbi, M, Berrebi, A, Lishner, M, Yerushazim, R, Yermiaku, T, Kosolov, V, Ambrosetti, Achille, Andreoli, Al, Huguet, F, Laurent, G, Orsucci, L, Forconi, F, Musuraca, G, Zinzani, Pl, Loscertales, J, Mcquillan, A, Cordingley, F, Leahy, M, Cazin, B, Taylor, Mulligan, S, Herbrecht, Cull, G, Seldon, M, Rowlings, P, Ludwig, H, Zojer, N, Solal Céligny, P, Pomponi, F, Savdkova, L, Kozák, T, Christiansen, I, Pérez, I, Campbell, P, Canales Albendea, M, De Paz, R, Arthur, C, Gisselbrecht, C., Eichhorst B.F., Fischer K., Fink A.M., Elter T., Wendtner C.M., Goede V., Bergmann M., Stilgenbauer S., Hopfinger G., Ritgen M., Bahlo J., Busch R., Hallek M., and Zinzani P.L.

Subjects
Male, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, Immunology, Medizin, Antineoplastic Combined Chemotherapy Protocols, Blood Cell Count, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Prognosis, Recurrence, Remission Induction, Tomography, X-Ray Computed, Physical examination, Biochemistry, Chemoimmunotherapy, medicine, Chronic, Tomography, Leukemia, medicine.diagnostic_test, business.industry, B-Cell, Cancer, Cell Biology, Hematology, medicine.disease, Lymphocytic, imaging techniques, X-Ray Computed, Fludarabine, Surgery, chronic lymphocytic leukemia, Radiology, business, Progressive disease, medicine.drug
Abstract

The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results